General Information of Drug (ID: DMBXEG9)

Drug Name
Intetumumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMBXEG9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cilengitide DMEAOZ0 Rheumatoid arthritis FA20 Phase 3 [3]
ATN-161 DM4T9RS Renal cell carcinoma 2C90 Phase 2 [4]
VLTS-589 DM4O17U Peripheral vascular disease BD4Z Phase 2 [5]
Fluciclatide F-18 DME01HT Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
SF0166 DM4NK3J Diabetic macular edema 9B71.02 Phase 1/2 [7]
AMEP DMFELMQ Melanoma 2C30 Phase 1 [8]
Vitaxin DMHCLVQ Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [9]
SB-267268 DMIBFAV Osteoporosis FB83.0 Discontinued in Phase 1 [10]
SB-273005 DMV7M1H Osteoporosis FB83.0 Discontinued in Phase 1 [11]
PS-388023 DM8P05S Ocular disease 1F00.1Z Terminated [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-V/beta-3 (ITGAV/B3) TT69TQN ITAV_HUMAN-ITB3_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT00537381) An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer. U.S. National Institutes of Health.
2 A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011 Jul 26;105(3):346-52.
3 The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.PLoS One.2009;4(2):e4449.
4 A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006 Sep;5(9):2271-80.
5 AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis. 2013(4), Page 35.
6 Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.J Nucl Med.2009 Jan;50(1):116-22.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Gene Ther.2015 Jul;22(7):578-90.
9 Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood. 2000 Jan 15;95(2):368-74.
10 SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5.
11 Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthri... Arthritis Rheum. 2001 Jan;44(1):128-37.
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.